BB BIOTECH NAM. SF 0,20/ CH0038389992 /
3/22/2023 9:54:22 AM | Chg. +0.30 | Volume | Bid3/22/2023 | Ask9:54:22 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
53.30EUR | +0.57% | 2,077 Turnover: 110,671.10 |
53.10Bid Size: 982 | 53.30Ask Size: 364 | 2.97 bill.EUR | - | - |
GlobeNewswire
6/17/2021
Aleva Neurotherapeutics Recruits First Patient into its PMCF Study with its directSTIM™ Directional ...
GlobeNewswire
12/16/2019
Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raise...
GlobeNewswire
10/19/2018
Global Neurostimulation Devices Market Report 2018-2030: Focus on Invasive Devices Such as SCS, DBS,...
GlobeNewswire
1/2/2018
Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications
GlobeNewswire
10/19/2017
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
GlobeNewswire
12/2/2016
Successful launch of BB Healthcare Trust plc on the London Stock Exchange - initial issue volume GBP...
GlobeNewswire
7/29/2016
Bellevue Group with half-year operating profit of CHF 6.8 mn - increase of assets under management t...
GlobeNewswire
7/15/2016
BB Biotech AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the...
GlobeNewswire
7/14/2016
BB Biotech AG : Publication pursuant to §26a WpHG (the German Securities Trading Act) with the aim o...
GlobeNewswire
6/23/2016
BB Biotech AG :Release of the Home Member State according to Article 2c of the WpHG (the German Secu...